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ttp://dx.doi.org/10.1016/j.jmoldx.2016.04.001To develop hepatitis C virus (HCV) direct-acting antiviral (DAA) drugs that can treat most HCV genotypes
and offer higher barriers for treatment-resistant mutations, it is important to study resistance-associated
variants (RAVs). Current commercially available RAV detection assays rely on genotype- or subtype-speciﬁc
template-dependent PCR ampliﬁcation. These assays are limited to genotypes and subtypes that are often
prevalent in developed countries because of availability of public sequence databases. To support global
clinical trials of DAAs, we developed and validated a template-independent (TI) next-generation
sequencing (NGS) assay for HCV whole genome sequencing that can perform HCV subtyping, detect HCV
mixed genotype or subtype infection, and identify low-level RAVs at a 5% fraction of the viral population
with sensitivity and positive predictive value  0.9. We compared TI-NGS with commercial genotype- or
subtype-speciﬁc Sanger sequencing assays, and found that TI-NGS both conﬁrmed most of variants called
by Sanger sequencing and avoided biases likely caused by PCR primers used in Sanger sequencing. To
conﬁrm TI-NGS assay’s variant calls at the discrepant positions with Sanger sequencing, we custom
designed template-dependent NGS assays and obtained 100% concordance with the TI-NGS assay. The
ability to reliably detect low-level RAVs in HCV samples of any subtype without PCR primer-related
bias makes this TI-NGS assay an important tool in studying HCV DAA drug resistance. (J Mol Diagn 2016,
18: 643e656; http://dx.doi.org/10.1016/j.jmoldx.2016.04.001)Supported by institutional funding from Merck & Co.
Disclosures: All authors are currently employed by Merck & Co, Inc. and
have received the company’s stock awards.Hepatitis C is a liver infection caused by the blood-borne
virus hepatitis C virus (HCV). According to the Centers for
Disease Control and Prevention, an estimated 170 million
individuals worldwide are chronically infected with HCV,
and approximately 10% to 20% of them will develop severe
liver diseases.1 HCV is a single-stranded RNA virus with a
high degree of genetic variability and nucleotide sequence
diversity, caused by the lack of a proofreading 30 to 50
exonuclease activity in its RNA-dependent RNA
polymerase.2 The complex genetic variability of HCV has
been classiﬁed into four hierarchical strata: genotypes,
subtypes, isolates, and quasispecies.3 A consensus proposal
for HCV classiﬁcation was initially presented in 20054 and
updated in 2014,5 which classiﬁed HCV isolates into seven
genotypes (GTs) and 67 conﬁrmed subtypes, with 24stigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgconﬁrmed subtypes belonging to GT 6. There are
geographical variations in genotype prevalence, with GT 1
and 3 more prevalent globally, whereas GT4 is more
prevalent in North Africa and the Middle East, and GT2 and
6 are found most frequently in East Asia.6 The most diverse
HCV genotype GT6 is prevalent in China and Southeast
Asian countries.7
For both traditional treatment with pegylated interferon
a/ribavirin and the currently available HCV direct-acting
antiviral (DAA) drugs, different genotypes and subtypes
of HCV have different antiviral treatment responses.8,9olecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Wei et alTherefore, accurate genotyping and subtyping of HCV is
needed for the selection of proper treatment regimens. In the
developed world, most cases of HCV infection occur among
people who inject drugs (PWID).10 In clinical trials of DAA
drugs with PWID subjects, mixed HCV genotype/subtype
infections observed in PWID11 can affect treatment success.
A sensitive assay that can detect low levels of genotypes
and/or subtypes not targeted by DAA drugs in mixed
infected PWID is required for the accurate evaluation of
DAA treatment success. In chronically infected patients,
HCV exists as a complex mixture of genetically distinct but
closely related genomes described as a quasispecies,12
caused by continually high viral production combined
with error-prone RNA replication. The quasispecies provide
a large pool of genetic variants that can adapt to new
selection pressures such as host cell defense and antiviral
treatments, resulting in chronic infection and HCV drug
resistance.13 For the development of interferon-free DAA
drugs that are pan-genotypic and have a higher barrier for
resistance variants that either exist before treatment or
emerge during treatment, it is important to have a sensitive
sequencing assay that can detect viral genetic changes and
potential DAA treatment resistanceeassociated variants
(RAVs) for all HCV genotypes and subtypes.
Current commercially available RAV detection assays are
template dependent, which means that PCR primers were
designed on the basis of conserved nucleotide sequences
shared among isolates of particular HCV genotypes or
subtypes to amplify speciﬁc genes targeted by DAA drugs.
This approach requires that the particular genotypes
and subtypes are sufﬁciently represented in public nucleo-
tide sequence databases. It also requires a robust and
accurate subtyping assay that can analyze all encountered
subtypes before performing the subtype-speciﬁc RAV
assays. Although there are several commercial RAV assays
validated for the well-known genotypes or subtypes such as
1a and 1b, samples with known genotype but unknown
subtypes or subtypes with limited nucleotide sequence in-
formation pose challenges to such a template-dependent
approach. That is especially true for samples of GT6, with
its large number of diverse subtypes, many of which are
poorly represented in sequence databases.
Herein, we describe a pan-genotypic template-independent
(TI) next-generation sequencing (NGS) assay for HCV whole
genome sequencing that can perform HCV subtyping, detect
mixed genotype or subtype infection, and identify RAVs.
The assay is built on an RNA-seq method using random
primed cDNA synthesis, combined with a simple RNA
extraction method, and a human rRNA depletion procedure
that eliminates the majority of non-HCV NGS reads observed
in previous methods.14 The assay can reliably detect RAVs at
a 5% fraction of the viral population with viral load of 106
IU/mL with both high sensitivity and positive predictive
value. The ability to reliably detect low-level RAVs in HCV
samples of any subtype with a robust experimental procedure
makes our TI-NGS assay a promising tool in studying the644dynamics of viral genetic changes with HCV DAA treat-
ments to enable better clinical outcomes.
Materials and Methods
HCV Specimens
For assay development, three high viral load HCV plasma
samples were purchased from Discovery Life Sciences (Los
Osos, CA), and two HCV serum samples were purchased
from SeraCare Life Sciences (Milford, MA). These ﬁve
commercial samples represented ﬁve subtypes and four
genotypes: GT1a, 1b, 2b, 4a, and 6a. Plasma samples
collected from normal healthy volunteers (NHVs) by
BioreclamationIVT (New York, NY) were pooled and
conﬁrmed to be HCV negative and used for serial titrations
of the high viral load commercial HCV samples. To mimic
HCV mixed genotype/subtype infections, the commercial
GT1a and 1b samples were also mixed at 5%, 10%, 25%,
50%, 75%, 90%, and 95% of 1a in a 1b background at a
total viral load of 106 IU/mL, using the viral load infor-
mation provided by the vendors.
Seventeen clinical plasma samples described in this
article were collected from a clinical trial with HCV DAA
drugs (ClinicalTrials.gov, identiﬁer: NCT01932762). They
were from 10 HCV patients whose samples were initially
genotyped as GT6 by the Siemens VERSANT HCV
Genotype INNO-LiPA 2.0 Assay (Malvern, PA). More
accurate HCV subtyping assay using NS5B small amplicon
Sanger sequencing based phylogenetic analysis15 showed
that two samples from two patients actually belong to GT1b.
Among the 10 patients, eight were treated successfully with
HCV DAA drugs and thus only their baseline screening
samples were collected and analyzed with the sequencing
assays. However, there were two GT6 patients who failed
HCV DAA treatment. For each of them, multiple samples
were collected on different follow-up dates after treatment.
Please note that all patients enrolled in the clinical trial
provided informed consent in writing, and the study proto-
col was in accordance with the global standards of the In-
ternational Conference on HarmonizationeGood Clinical
Practices, the Council for International Organizations of
Medical Public Policy Statement: Clinical Trial Ethics
Sciences International Ethical Guidelines for Biomedical
Research Involving Human Subjects (CIOMS, 2002), the
Pharmaceutical Research and Manufacturers of America
(PhRMA, 2009) Principles on Conduct of Clinical Trials,
applicable local regulatory requirements, and following the
ethical principles that have their origin in the Declaration of
Helsinki.
In VitroeTranscribed HCV RNA Sample
HCV GT1a (H77) replicon cell lines were treated with
various concentrations of the HCV NS3/4A protease in-
hibitor grazoprevir and the NS5A replication inhibitorjmd.amjpathol.org - The Journal of Molecular Diagnostics
HCV Resistant Variant Detection with NGSelbasvir in studies to deﬁne sequence changes that confer
resistance to the compounds.16 RNA samples extracted from
these replicon cell lines were used as templates to generate
cDNA corresponding to the NS3 to NS5B segment of the
HCV polyprotein. The resulting cDNAs were then stably
cloned into the pCR-XL-TOPO vector by Genscript
(Piscataway, NJ). From the 162 available cDNA-bearing
plasmids, two individual plasmids that differed from
each other at 60 nucleotide positions were selected for
in vitroetranscribed RNA synthesis. First, the plasmid DNA
was extracted using the QIAprep Spin Miniprep kit (Qiagen,
Valencia, CA), digested with restriction enzyme Mlu, and
puriﬁed with phenol/chloroform. Sense-stranded RNA
transcripts with total length of 6440 nucleotides were
then generated for each of the two plasmids using the
HiScribe T7 High Yield RNA Synthesis Kit (New England
Biolabs, Ipswich, MA), according to the manufacturer’s
instructions. They were puriﬁed and concentrated with RNA
Clean & Concentratore5 (Zymo Research, Irvine, CA) and
their concentrations were determined by the NanoDrop
spectrophotometer. Mixtures of 0%, 1%, 3%, 5%, 10%,
25%, and 100% of in vitroetranscribed (IVT) RNA of
Plasmid 1 in the background of IVT RNA of Plasmid 2 were
made at a RNA quantity equivalent to 106 copies of HCV to
estimate sensitivity, speciﬁcity, positive predictive value
(PPV), and negative predictive value (NPV) of the TI-NGS
assay. We also spiked 2.5  105 copies equivalent HCV
IVT RNA mixture samples into RNA extracted from 0.2 mL
of NHV plasma to evaluate TI-NGS assay’s sensitivity and
precision in detecting expected variants of HCV RNA
samples in human plasma RNA background.
RNA Extraction from Plasma Specimens
After thawing, 0.22 mL of plasma was centrifuged at
1500  g at 4C for 10 minutes to pellet debris and insol-
uble components. Then, 0.2 mL of supernatant was trans-
ferred into a new 1.5-mL tube for RNA extraction with the
ZR Viral RNA Kit (Zymo Research) per the manufacturer’s
protocol, except for the added step of incubating the plasma/
ZR Viral RNA Kit buffer mixture at room temperature for
5 minutes after mixing 0.6 mL of Viral RNA Buffer with the
plasma supernatant. With the 15-mL elution volume, the
ﬁnal recovered RNA volume was approximately 14 mL.
Human rRNA Depletion and DNAse I Treatment
A total of 12 mL of extracted RNA was treated by the
NEBNext rRNA Depletion Kit (New England Biolabs) to
remove human cytoplasmic (5S rRNA, 5.8S rRNA, 18S
rRNA, and 28S rRNA) and mitochondrial (12S rRNA and
16S rRNA) ribosomal RNA, and potential genomic DNA
contamination. Because of the low input mass of extracted
RNA (concentrations <0.25 ng/mL), major modiﬁcations
were made to the manufacturer’s protocol to obtain sufﬁ-
cient yields of NGS library for NGS runs. The modiﬁcationsThe Journal of Molecular Diagnostics - jmd.amjpathol.orginclude the reduction of NEBNext rRNA Depletion Solution
from 1 to 0.5 mL, the decrease of RNAse H from 2 to
0.5 mL, the addition of a 20 minutes 65C heat inactivation
step after RNAse H treatment, and the decrease of DNase I
incubation time from 30 minutes to 15 minutes. The ﬁnal
volume of rRNA depleted RNA was approximately 6 mL.
Template-Independent NGS Library Preparation
A total of 5mLof the rRNA-depleted RNAwas converted into
an Illumina platform compatible NGS library with NEBNext
Q5 Hot Start HiFi PCR Master Mix (New England Biolabs).
Because this kit was originally designed for total RNA sam-
ples with input masses of 100 ng to 1 mg, we made the
following modiﬁcations to adapt the kit for the low input
masses of RNA isolated from 0.2 mL of plasma. First, the
RNA fragmentation step was eliminated because it reduced
the number of NGS reads aligned to the HCV genome. Sec-
ond, the incubation time for the ﬁrst strand cDNA synthesis
was increased to 50 minutes for the conversion of the 9.6-kb
long HCV RNA into cDNA. For adaptor ligation, NEBNext
adaptor was diluted to 1:50 to reduce the level of adaptor-
dimer in the ﬁnal NGS library. For the puriﬁcation of the
ligation reaction using AMPure XP beads, size selection
conditions were selected for approximate insert size of 300 to
450 bp. For PCR library enrichment, 2 mL instead of original
2.5 mL of volume was chosen for each PCR primer to reduce
primer presence in the ﬁnal NGS library. For the PCR step of
enriching Illumina adaptor ligated DNA, PCR cycle number
was increased to 22 from the original 15, and annealing and
extension time was increased to 90 seconds for the longer
inserts. For the puriﬁcation of the PCR of the NGS library
preparation, the library puriﬁcation step with Agencourt
AMPure XP beads was repeated one more time to remove the
presence of primer and adaptor-dimer caused by the lowRNA
input mass.
Template-Independent NGS Library Quality Assessment
and Quantiﬁcation
The NGS library quality was assessed with Agilent’s High
Sensitivity DNA Analysis Kit (Santa Clara, CA) on an
Agilent 2100 Bioanalyzer. The library quantity was deter-
mined with the KAPA Library Quantiﬁcation Kit Illumina
Platform (KAPA Biosystems, Boston, MA).
Estimation of Sensitivity, Speciﬁcity, Positive
Predictive Value, and Negative Predictive Value of
Template-Independent NGS Assay
Sensitivity was calculated as the number of correct variants
called by the TI-NGS assay at the speciﬁed variant calling
frequency cutoff, divided by the expected number of correct
variant calls. Sensitivity is inﬂuenced by false negatives,
which were generated when the TI-NGS assay could not
detect the expected variants. Speciﬁcity was calculated as645
Wei et althe number of correct nonvariant positions called by the TI-
NGS assay at the speciﬁed variant calling frequency cutoff,
divided by the expected number of nonvariant positions.
PPV was calculated as the number of correct variants called
by the TI-NGS assay divided by all variant calls made by
the TI-NGS assay. PPV is inﬂuenced by the false-positive
variants called by the assay. NPV was calculated as the
number of the correct nonvariant positions called by TI-
NGS divided by all nonvariant positions called by TI-NGS.
When using the IVT HCV RNA mixture samples to esti-
mate sensitivity and PPV, the expected number of correct
variants is 60 (the number of positions that the two IVT
RNA samples differ from each other), and the expected
number of correct nonvariant positions is 6380. For the
commercial HCV plasma samples, sensitivity and PPV were
calculated with the nucleotide positions located in HCV
polyprotein from NS2 to NS5B. Because the exact variant
and nonvariant positions are not unknown for the com-
mercial HCV samples, the variants called by the TI-NGS
assay of the highest viral load dilution at the speciﬁed
variant calling frequency cutoff were treated as the expected
correct variants, and the rest of the nucleotide positions were
treated as correct nonvariant positions.
Template-Dependent NGS Assay Design and Related
NGS Library Preparation
For the two patients who failed HCV DAA treatment,
multiple clinical samples, including both the baseline
screening sample and different time point follow-up sam-
ples, were collected. One patient had a treatment failure
sample with viral load <2000 IU/mL, which was too low to
be analyzed by TI-NGS. To analyze the low viral load
sample and to conﬁrm the accuracy of variant calls of
TI-NGS for the higher viral load samples of these two
patients, template-dependent (TD) NGS assays were custom
designed for each of the two patients using the conserved
sequences obtained through TI-NGS from all higher viral
load samples. For each patient, a reverse transcription (RT)
primer located at the 30 untranslated region and a set of PCR
primers and nested PCR primers targeting NS3/4A, NS5A,
and NS5B were designed. The reverse transcription re-
actions were performed with SuperScript IV First-Strand
Synthesis System (ThermoFisher Scientiﬁc, Waltham, MA).
The PCR was performed with Platinum PCR SuperMix
High Fidelity (ThermoFisher Scientiﬁc) with 35 PCR cy-
cles. For samples with viral load <2000 IU/mL, a nested
PCR was performed with an additional 35 PCR cycles. PCR
DNA was puriﬁed with QIAquick PCR Puriﬁcation Kit
(Qiagen) and the PCR amplicon was assessed with Agilent’s
DNA 12000 Kit on Bioanalyzer. The DNA concentration
was measured with NanoDrop, and the Qubit dsDNA HS
Assay Kit on the Qubit 2.0 Fluorometer (ThermoFisher
Scientiﬁc). A total of 0.2 ng of puriﬁed PCR DNA was used
to make an Illumina NGS library using Nextera XT DNA
Library Preparation Kit (Illumina, San Diego, CA). The646NGS libraries were quantiﬁed with the KAPA Library
Quantiﬁcation Kit Illumina Platform.
MiSeq Run
Both TI-NGS and TD-NGS libraries were run on the MiSeq
instrument with Illumina’ MiSeq Reagent Kit v3 with
260  260 cycles. The loading density was 15 pM and typi-
cally eight TI-NGS libraries were analyzed per MiSeq run.
Building an In-House HCV Reference Genome Database
for HCV Subtyping
There are a total of 112 accession numbers for HCV reference
genomes in the in-house HCV BLAST database. They are the
accession numbers listed in “Table 1 Conﬁrmed HCV
Genotypes/Subtypes (May 2015)” on the International Com-
mittee on Taxonomy of Viruses (ICTV) website (https://talk.
ictvonline.org/ictv_wikis/ﬂaviviridae/w/sg_ﬂavi/35.table-
1-conﬁrmed-hcv-genotypessubtypes-may-2015, last accessed
September 16, 2015) that have corresponding FASTA
sequences in the Los Alamos HCV Database (http://hcv.lanl.
gov/content/index, last accessed September 16, 2015), plus
four additional reference genomes in the National Center for
Biotechnology Information database. The FASTA sequences
of the threeHCVDAA targets (NS3/4A,NS5A, andNS5B) for
each of the aforementioned accession numbers were then
extracted from the Los Alamos HCVDatabase. As a result, for
each of the three targets, one corresponding database was
generated, containing the FASTA sequences for the 112
accession numbers.
HCV Subtyping
Before HCV subtyping, the followed QC ﬁlters were
implemented to ensure that only good quality NGS FASTQ
reads would be used for the downstream subtyping analysis.
First, paired-end FASTQ reads were merged using FLASH
(version 1.2.11).17 Next, we used the FASTX tool kit version
0.0.13 (http://hannonlab.cshl.edu/fastx_toolkit, last accessed
September 16, 2015) to remove reads with a quality score
of <30 for >5% of the read length, and/or with read
length <250 bp. For HCV subtyping analysis, we converted
the remaining FASTQ reads into FASTA sequences to
BLAST them against each of the three in-houseHCV reference
genome databases. For each FASTA read that was aligned to
any of the three HCV targets, we assigned the read with its
single best matching HCV subtype, provided its alignment
length was at least 100 bp and the alignment rate was at least
85%. Then, for each sample, and for each of the three targets,
we tabulated the counts of the best matched subtypes.
HCV Variant Calling at Nucleotide Sequencing Level
There are several steps involved in HCV variant calling for
RAV detection, which are described below in detail.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Percentage of TI-NGS Reads Aligned to HCV Genome and Average Read Coverage of HCV DAA Targets for Clinical HCV Samples
Patient
alias
HCV
subtype
Viral load
(IU/mL)
Treatment
outcome Time point
No. of ﬁltered
MiSeq paired
end reads*
Filtered
reads aligned
to HCV (%)y
Average coverage for
individual DAA target
NS3/4A NS5A NS5B
P1 6t 39,617 Failure Failure follow-up 1 6,447,693 0.3 793 987 525
P2 6e 85,848 SVR Visit 1 screening 7,296,182 0.7 1953 2659 1388
P1 6t 337,504 Failure Failure follow-up 2 3,645,786 1.9 2848 4226 2101
P3 6a 412,948 SVR Visit 1 screening 2,390,981 2.7 3313 2768 2171
P4 6q 834,020 Failure Failure follow-up 3 3,184,398 2.1 3218 4122 2088
P5 6e 1,130,000 SVR Visit 1 screening 2,812,174 8.4 8446 14,629 8351
P1 6t 1,565,608 Failure Failure follow-up 3 3,360,457 11.0 16,095 23,940 10,444
P6 6a 3,269,519 SVR Visit 1 screening 2,815,837 19.1 22,803 26,105 16,916
P4 6q 4,404,921 Failure Failure follow-up 1 3,856,674 27.3 48,083 71,122 33,143
P4 6q 4,722,667 Failure Visit 1 screening 3,446,473 15.1 25,385 31,712 16,079
P7 1b 6,856,560 SVR Visit 1 screening 3,328,765 39.2 58,897 79,353 31,575
P1 6t 11,542,929 Failure Visit 1 screening 3,235,751 35.4 50,656 66,549 34,615
P8 6e 13,081,539 SVR Visit 1 screening 3,528,975 38.4 64,300 65,048 43,970
P4 6q 18,230,473 Failure Failure follow-up 2 3,921,805 50.9 94,061 12,7636 60,401
P9 1b 19,774,342 SVR Visit 1 screening 3,941,799 53.0 10,1690 14,5315 49,676
P10 6e 21,300,000 SVR Visit 1 screening 2,751,066 26.6 26,006 35,220 30,760
Even though 16 clinical samples were collected from 10 different patients (alias P1 to P10, with P1 and P4 representing two patients who failed HCV DAA
treatment) with different HCV subtypes, the percentages of TI-NGS reads aligned to HCV genome are correlated with the HCV viral loads among the clinical
samples. For each sample, the percentage of TI-NGS reads aligned to the HCV genome is highly correlated with average read coverage of HCV DAA targets NS3/
4A, NS5A, and NS5B. Please note that the table is sorted in the increasing order of HCV viral load.
*Filters used on MiSeq NGS reads: 30 end base quality Q15 trimming and minimal read length of 100 trimming.
yPercentage of ﬁltered MiSeq NGS reads aligned to the HCV consensus sequence of each sample.
DAA, direct-acting antiviral; HCV, hepatitis C virus; SVR, sustained virologic response (indicating HCV treatment success); TI-NGS, template-independent
next-generation sequencing.
HCV Resistant Variant Detection with NGSQuality Control Filtering of FASTQ Reads
We used cutadapt software version 1.8.1 (http://cutadapt.
readthedocs.org/en/latest/guide.html, last accessed
September 16, 2015) to trim the 30 end nucleotides in the
reads so that the average base quality score of the remaining
nucleotides would be at least 15. Only the quality trimmed
FASTQ reads that were at least 100 nucleotides long were
retained for the downstream analyses.
Alignment to HCV Reference Genome or Consensus Sequence
Bowtie2 version 2.1.0 (http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml, last accessed September 16, 2015)
was used to align the QC ﬁltered FASTQ reads to the HCV
reference genome of the best matching subtype as deter-
mined by HCV subtyping. SAMtools version 1.2 (http://
samtools.sourceforge.net, last accessed September 16,
2015) was then used to generate the pileup ﬁle for the
initial alignment. Using the SAMtools generated pileup
ﬁle, the ﬁrst iteration of the consensus sequence (conseq1)
was generated using the algorithm described in Generation
of Consensus Sequence. To iteratively improve the accu-
racy of HCV alignment, we realigned the FASTQ ﬁles to
conseq1, regenerated the pileup ﬁle, and generated the
second iteration of the consensus sequence (conseq2). The
FASTQ ﬁles were again mapped to conseq2 to generate the
last round of the pileup ﬁle, which was used to generate the
list of variant calls with the algorithms listed in Variant
Calling.The Journal of Molecular Diagnostics - jmd.amjpathol.orgGeneration of Consensus Sequence
For generation of a consensus sequence used in the afore-
mentioned Alignment section, VARSCAN version 2.3.6
(http://varscan.sourceforge.net, last accessed September 16,
2015) was used to report the read depth for each nucleotide at
the positions in the pileup ﬁle generated from the Alignment
section outlined above using the readcounts function. A base
quality score cutoff of Q20 was applied to ﬁlter out low
quality reads before counting the allelic read depth. Next, a
custom R-script (Supplemental Code S1) was written to parse
the VARSCAN output into a consensus sequence containing
International Union of Pure and Applied Chemistry codes.
More speciﬁcally, for the positions that had more than one
nucleotide detected at  5%, the appropriate ambiguous In-
ternational Union of Pure and Applied Chemistry codes were
assigned. A coverage cutoff of 10 was used on Q20 ﬁltered
reads when generating the consensus sequence for each
position, and the positions that lacked sufﬁcient coverage
were replaced with the corresponding reference allele.
Insertions and deletions (indels) were incorporated into the
consensus sequence only when the indels were present as the
major allele of the viral population.
Variant Calling
We implemented a quality-based algorithm for HCV variant
calling with the last round of pileup ﬁle aforementioned in
Alignment. The QC parameters deﬁned below were used in
the variant calling algorithm: i) Coverage: deﬁned as the647
Figure 1 HCV whole genome next-generation sequencing (NGS) read coverage for serially diluted four commercial HCV samples with template-independent
NGS assay. Comparison of read coverage (number of NGS reads with Q20 or higher base quality scores at each nucleotide position across the HCV genome) of
four commercial HCV samples with 1:10 serially diluted viral loads. Even though different samples have distinct read coverage patterns across the HCV genome,
each sample has a consistent coverage pattern across different viral loads. (For the GT1a sample, the highest viral load is 4.8  106 IU/mL; for GT1b sample,
7.0  106 IU/mL; for GT2b sample, 1.2  107 IU/mL; and for GT6a sample, 1.7  107 IU/mL). UTR, untranslated region.
Wei et alread depth of the reads passing base quality Q20 ﬁlter at each
nucleotide position of the HCV genome, ii) Strand bias:
calculated with max (VpCm, VmCp)/(VpCm þ VmCp), as
described in Torrent Suite software’s Torrent Variant Detec-
tion Algorithms version 3.4 (Thermo Fisher Scientiﬁc,
Waltham, MA; Vp is the number of alternative reads on pos-
itive strand, Cp is the total number of reads on positive strand,
Vm is the number of the alternative reads on minus strand, and
Cm is the total number of reads on minus strand), iii) Variant
allele fraction (VAF): deﬁned as variant allele’s read depth
divided by total read depth at each nucleotide position, and iv)
Homopolymer: a stretch of sequence containing six or more
consecutive identical nucleotides. We deﬁned a variant as No
Call if it had Q20 coverage <300, and/or with strand bias
>0.95. For variants that were either 0 or 1 nucleotide away
from a homopolymer, a warning would be raised. In addition,
only those variants passing the QC ﬁlters and with VAF 5%
would be reported.
Results
Full Genome Sequencing of HCV Samples Using the
Template-Independent NGS Assay
Five commercial HCV plasma or serum samples representing
four different HCV genotypes were serially diluted withHCV
negative plasma samples at various viral loads, with the initial648viral loads determined by the individual clinical laboratories
that supplied the samples to the tissue vendors. Supplemental
Table S1 reports viral loads, HCV subtypes (determined by
the BLAST algorithm), percentage of TI-NGS reads aligned
to theHCVgenome, and the average read coverage for each of
the three HCVDAA targets. Figure 1 shows the TI-NGS read
coverage at each nucleotide position across the HCV genome
for four such commercial samples, demonstrating that each
HCV sample has its own distinct coverage pattern that is
consistent among different viral load dilutions of the same
sample. This is likely caused by RNA secondary structure
speciﬁc to each independent HCV genome sequence. Among
the ﬁve commercial samples, one sample’s initial genotype
(GT1) did not match the subtype (GT6a) determined by the
BLAST algorithm. Further investigation found that the clin-
ical laboratory used the Abbott RealTime HCV Genotype II
assay (Abbott Molecular Inc., Des Plaines, IL) for HCV
genotyping, which is known for potential mistyping between
GT1 and 6 samples because of the cross-reaction of the PCR
probes.Within each sample, the percentage of reads aligned to
the HCV genome and the average coverage highly correlated
with viral loads (Supplemental Table S1). However, there is
less correlation between HCV read coverage and viral loads
among different samples, likely because of viral load being
determined by different methods.
Different from the commercial samples, the viral loads for
the clinical samples collected from the HCV DAA treatmentjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 HCV whole genome next-generation sequencing read coverage for clinical samples collected at multiple time points from two patients with HCV
direct-acting antiviral treatment failure. For each patient, the earliest collection date indicates the baseline screening sample and the subsequent dates are the
samples collected after treatment.
HCV Resistant Variant Detection with NGSstudy were determined with the same assay. The percentage of
NGS reads aligned to the HCV genome and the average
coverage highly correlatedwith viral loads, even though the 16
clinical samples were collected from 10 patients by different
clinical sites and they belonged to two genotypes and various
subtypes (Table 1). The HCV subtypes determined by the
BLAST algorithm were in 100% agreement with the results
from the NS5B small amplicon sequencingebased phyloge-
netic analysis, demonstrating the accuracy of the BLAST al-
gorithm used for TI-NGS subtyping. The percentage of NGS
reads aligning to the HCV genome started from 8% at
1.1  106 IU/mL and increased to 53% at 2.0  107 IU/mL
(Table 1). Except for the sample with the lowest viral load at
4.0  104 IU/mL, all other samples had average coverage
>1000 starting from 8.6  104 IU/mL. Distinct coverage
patterns were also observed for the clinical samples. For each
of the two patients who failed HCV DAA treatment, the
multiple samples collected from the same patient at various
time points before and after treatment had the same coverage
pattern, which was expected because these samples had almost
identical nucleotide sequences except for the <1% variant
positions (Figure 2).
Detecting Low-Level Genotype/Subtype in Mixed
Infections with Template-Independent NGS
The commercial GT1a and 1b plasma samples were mixed
at the percentages of 1a versus 1b at 5%/95%, 10%/90%,The Journal of Molecular Diagnostics - jmd.amjpathol.org25%/75%, 50%/50%, 75%/25%, 90%/10%, and 95%/5% at
a total viral load of 106 IU/mL for each mixture sample. The
RNA samples extracted from these mixture samples were
analyzed with TI-NGS. For each of the seven 1a/1b mixture
samples, the NGS reads were blasted against the in-house
HCV sequence databases for the three HCV DAA targets
NS3, NS5A, and NS5B, resulting in 21 BLAST results.
Seventeen BLAST results had only expected GT1a or 1b
reads; the remaining four had only one or two reads among
thousands of reads that are not best matched to 1a or 1b,
representing <0.1% of the BLAST matched reads
(Supplemental Table S2). Measured 1a/1b ratios were
calculated for each mixture sample with the counts of the
NGS reads that are best matched to 1a or 1b at the three
DAA targets. The measured 1a/1b ratios and the expected
1a/1b ratios showed excellent correlation (r2 > 0.995)
(Figure 3). To improve assay sensitivity of detecting low-
level minor genotypes or subtypes, we combined the
counts of the BLAST results from the three HCV DAA
targets. The ratios of the combined counts (Figure 3) also
showed excellent correlation with the expected ratios. The
intercept values (approximately 1.9 in log2 scale, instead of
the expected 0) supported our hypothesis that the viral load
results of the commercial samples were not really compa-
rable, because of different laboratories using different
methods for viral load determination. Assuming that the
GT1a and GT1b samples would have similar best-matched
subtype counts at the same viral load, the intercept value649
Figure 3 Measured GT1a/1b ratios versus expected GT1a/1b ratios for HCV mixed infection detection. Commercial GT1a and 1b HCV samples were mixed at
the speciﬁed percentages using the viral load information provided by the tissue vendors. Measured GT1a/1b ratios were calculated using the number of next-
generation sequencing (NGS) reads that best matched 1a or 1b subtypes through BLAST against NS3, NS5A, NS5B, and the three genes combined. Highly
correlated ratios of measured GT1a/1b versus expected 1a/1b show that template-independent NGS assay can accurately detect the mixed HCV infection. Data
are presented in log2 scale.
Wei et alindicated that the percentage of 1b in the supposed 50%
1a/50% 1b mixture was approximately 21%, and the per-
centage of 1b in the supposed 95% 1a/5% 1b mixture was
approximately 1.4%, more sensitive than the 5% cutoff value
required by a clinical study for mixed infection detection.
Sensitivity, PPV, and Sequencing Error Estimation of
Template-Independent NGS with in VitroeTranscribed
HCV RNA Samples
Two HCV GT1a plasmids that differed at 60 nucleotide po-
sitions were used to generate two corresponding IVT RNA
samples of 6440 nucleotides in length. Because the expected
variants and nonvariants are known for these samples, they
were used to estimate sensitivity, speciﬁcity, PPV, NPV, and
sequencing error of the TI-NGS assay. The HCV IVT RNA
samples in the absence of human plasma RNA were used to
evaluate TI-NGS assay performance starting from the ﬁrst
step of RNA-seq, which is the ﬁrst strand cDNA synthesis.
For these samples, the IVT RNA from Plasmid 1 was added
into a background of the IVTRNA from Plasmid 2 at 0%, 1%,
3%, 5%, 10%, 25%, and 100%, at a combined RNA input
equivalent to 106 copies of HCV. Correlations between
measured VAFs and expected VAFs are excellent for all 60
expected positions, with the lowest r2 value being 0.992,
demonstrating the linearity of measured VAFs of the TI-NGS
assay. Examples of such correlation at 12 of the expected650variant positions are shown in Figure 4. To study the inﬂuence
of human rRNA depletion and genomic DNA removal steps
and human mRNA background, IVT RNA mixture samples
with equivalent 2.5  105 copies of HCV were also spiked
into 200 mL equivalent NHV plasma RNA samples to mimic
RNA samples extracted from HCV plasma samples. Table 2
shows the estimated sensitivity, speciﬁcity, PPV, and NPV
with VAF cutoff values set at 1%, 3%, 5%, and 10%,
respectively. It shows that for IVT RNA samples without
human plasma RNA background, the TI-NGS assays have
excellent sensitivity, speciﬁcity, and NPV (all >0.95)
beginning at the 1% VAF cutoff, and excellent PPV begin-
ning at the 3%VAF cutoff. For IVTRNA samples spiked into
human plasmaRNA samples and going through human rRNA
depletion treatment, excellent sensitivity and PPV are shown
at 5% VAF cutoff (the 3% mixture sample was not tested).
Table 3 reports the estimated sequencing error of the TI-NGS
assay, showing the consistently low background VAFs at the
expected 6380 nonvariant positions, although the human
plasma RNA and/or human rRNA depletion step slightly
increased the sequencing error.
Concordance between TI-NGS and Genotype/
Subtype-Speciﬁc Sanger Sequencing
Among the 17 clinical HCV samples, one had a viral load of
approximately 1500 IU/mL, which was too low to bejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Correlation between measured variant allele fraction (VAF) versus expected VAFs at positions with expected variants. Two in vitroetranscribed
(IVT) HCV RNA samples differing at 60 nucleotide positions were mixed at various percentages to mimic different expected VAFs. The expected VAFs are the
percentages of one IVT RNA of the mixed RNA samples. Measured VAFs at the indicated 12 nucleotide positions were selected as examples to demonstrate that
the template-independent next-generation sequencing assay can accurately estimate the VAFs of expected variants.
HCV Resistant Variant Detection with NGSanalyzed by TI-NGS. For the rest of the 16 samples, a
comparison was made between nucleotide sequencing
results of TI-NGS and commercial Sanger sequencing of
NS3/4A and NS5A. For the two samples belonging to
GT1b, commercially validated genotype-speciﬁc Sanger
sequencing assays were used by a contract research orga-
nization for the full length sequencing of NS3/4A and
NS5A. Because the contract research organization did
not have genotype-speciﬁc Sanger sequencing assays for
GT6, they custom-designed four subtype-speciﬁc SangerTable 2 Estimation of Sensitivity, Speciﬁcity, PPV, and NPV of TI-NGS
VAF
cutoff (%)
IVT RNA of
plasmid 1 (%)
Equivalent
copies of HCV
Presence of human
plasma RNA
1 1 106 No
3 3 106 No
5 5 106 No
10 10 106 No
5 5 2.5  105 Yes
10 10 2.5  105 Yes
Two IVT RNA samples synthesized from two plasmids that differ at 60 nucleotide
samples. These mixture samples have 6380 nonvariant positions and were used to
human plasma RNA were used to estimate sensitivity and PPV of TI-NGS starting f
thus do not reﬂect the inﬂuence of human rRNA depletion and genomic DNA re
estimate sensitivity and PPV of the TI-NGS assay, including the steps of human
IVT, in vitro transcribed; NPV, negative predictive value; PPV, positive predicti
variant allele fraction.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgsequencing assays. However, because of lack of publically
available GT6 nucleotide sequence databases, PCR
primers for full length ampliﬁcation of NS3 could not be
successfully designed for any of the four subtypes.
Therefore, only the ﬁrst 606 nucleotides of NS3 were
analyzed by Sanger sequencing and thus used in compar-
ison. The contract research organization successfully
designed subtype-speciﬁc PCR primers that could amplify
NS5A. However, for two samples, there were 138 and 276
nucleotide sequence gaps in NS5A that could not beAssay with HCV IVT RNA Mixture Samples
Human rRNA
depletion treatment Sensitivity Speciﬁcity PPV NPV
No 1.000 0.999 0.896 1.000
No 1.000 1.000 0.984 1.000
No 1.000 1.000 0.984 1.000
No 1.000 1.000 1.000 1.000
Yes 1.000 1.000 0.984 1.000
Yes 1.000 1.000 1.000 1.000
positions were mixed at various percentages to make HCV IVT RNA mixture
estimate sensitivity and PPV of TI-NGS. The IVT RNA samples not spiked into
rom the ﬁrst step of RNA-seq, which is the ﬁrst strand cDNA synthesis, and
moval. The IVT RNA samples spiked into human plasma RNA were used to
rRNA depletion and genomic DNA removal.
ve value; TI-NGS, template-independent next-generation sequencing; VAF,
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Table 3 Estimated Sequencing Errors of TI-NGS Platform
IVT RNA of
plasmid 1 (%)
Equivalent
copies of HCV
Presence of human
plasma RNA
Human rRNA
depletion treatment
Median
VAF (%)
95th Percentile
VAF (%)
99th Percentile
VAF (%)
0 106 No No 0.12 0.35 0.62
1 106 No No 0.14 0.38 0.64
3 106 No No 0.12 0.36 0.59
5 106 No No 0.12 0.37 0.62
10 106 No No 0.12 0.37 0.62
25 106 No No 0.13 0.38 0.64
100 106 No No 0.11 0.33 0.57
0 2.5  105 Yes Yes 0.22 0.72 1.09
5 2.5  105 Yes Yes 0.22 0.68 1.19
10 2.5  105 Yes Yes 0.21 0.55 0.80
Sequencing errors of the TI-NGS assay are estimated with HCV IVT RNA mixture samples that have 6380 nonvariant positions in the targeted HCV genome and
thus should have near zero VAF values.
HCV, hepatitis C virus; IVT, in vitro transcribed; TI-NGS, template-independent next-generation sequencing; VAF, variant allele fraction.
Wei et alanalyzed by Sanger sequencing and thus not used in our
comparison.
Using a 5% VAF cutoff value for variant calls for the
TI-NGS assay, we compared both nucleotide sequences and
nucleotide variant calls between Sanger sequencing and
TI-NGS. Supplemental Table S3 shows the high concor-
dance rates of nucleotide sequences between the two plat-
forms (ranging from 96.1% to 100%). It also shows that
high percentages of Sanger sequencing’s nucleotide variant
calls are conﬁrmed by TI-NGS (half the samples with 100%
conﬁrmation rate and only three with <90% conﬁrmationFigure 5 Conﬁrmation of variant allele fraction (VAF) measured by template-in
by custom-designed template-dependent NGS assays. VAFs of the baseline scre
measured by template-dependent (TD)-NGS custom-designed for the patient at N
652rate). Supplemental Table S4 lists the likely causes of
discrepant nucleotide variant calls between the two plat-
forms. For most of the samples, the discrepancy was likely
because of the lower sensitivity of Sanger sequencing
because many of the TI-NGS variants not called by Sanger
have VAF <25%. However, for several samples, especially
the ones from the two patients who failed HCV DAA
treatments, there are indications that Sanger sequencing
made wrong nucleotide variant calls because of PCR primer
caused bias in PCR ampliﬁcation. Because the subtype-
speciﬁc PCR and sequencing primers for Sanger weredependent next-generation sequencing (TI-NGS) assay with VAFs estimated
ening sample of patient P4 estimated by TI-NGS were compared to VAFs
S3, NS4A, NS5A, and NS5B.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
HCV Resistant Variant Detection with NGSdesigned based on limited public sequence information, it is
possible that the primers were designed on top of the
nucleotide positions that have variants linked to the
discrepant variant calls. For the HCV quasispecies that have
nucleotide sequences that match the PCR primers, their
variants within the PCR amplicon would be ampliﬁed; for
the quasispecies that have variants under the PCR primers,
their variants within the PCR amplicon would likely not be
ampliﬁed.Conﬁrming Template-Independent NGS Data with
Template-Dependent NGS Results
To conﬁrm the hypothesis that the discrepant nucleotide
variant calls were caused by Sanger sequencing’s PCR
primer bias, TD-NGS assays were custom designed for
each of the two treatment failure patients (Supplemental
Table S4) using the conserved nucleotide sequences ob-
tained from the TI-NGS assay from higher viral load
samples of the same patient. For each patient, patient-
speciﬁc reverse transcription primers and PCR primers
were designed to cover NS3, NS4A, NS5A, and NS5B.
TD-NGS conﬁrmed all of the TI-NGS variant calls listed
in Supplemental Table S4 that showed a discrepancy be-
tween TI-NGS and subtype-speciﬁc Sanger sequencing.
Figure 5 shows examples of excellent correlations of
VAFs between TI-NGS and TD-NGS in the four genes for
Patient P4’s baseline screening sample, conﬁrming not
only the accuracy of the nucleotide variant calls, but also
the accuracy of VAFs of nucleotide variants estimated
by TI-NGS.Table 4 High Sensitivity and PPV of Variant Calls of Serial Dilutions o
HCV subtype MiSeq NGS run date HCV viral load (IU/mL)
GT1a 5/15/2015 4.8  105
GT1b 4/28/2015 7.0  105
GT1b 4/28/2015 7.0  106
GT1b 5/9/2015 7.0  106
GT2b 5/15/2015 1.2  106
GT4a 12/18/2015 1.0  106
GT4a 3/4/2016 1.0  106
GT4a 12/18/2015 5.0  106
GT4a 3/4/2016 3.0  106
GT6a 5/9/2015 1.7  106
GT6a 4/17/2015 1.7  107
GT6a 4/17/2015 1.7  107
GT6a 4/17/2015 1.7  107
GT6a 4/17/2015 1.7  107
GT6a 5/9/2015 1.7  107
GT6a 4/3/2015 1.7  107
GT6a 4/3/2015 1.7  107
Serial dilutions of commercial HCV samples were extracted and analyzed with TI-N
run, the nucleotide variants with VAF  5% in the HCV genome from NS2 to NS5B w
were treated as nonvariants for sensitivity and PPV calculation. For samples with m
was calculated and the variants with average VAF  5% were treated as the expec
HCV, hepatitis C virus; NGS, next-generation sequencing; NPV, negative predic
The Journal of Molecular Diagnostics - jmd.amjpathol.orgPrecision of Variant Calls and Estimated Variant Allele
Fractions of TI-NGS
For HCV samples with viral loads at 106 IU/mL or above,
the VAFs of nucleotide variants are highly reproducible
within the same TI-NGS run and among different TI-
NGS runs, starting from RNA extraction. Supplemental
Figure S1 shows an example of good correlation of VAF
values of individual TI-NGS runs versus the average of
VAFs of the nine TI-NGS runs of the highest viral load
dilution using the commercial GT6a sample. The repro-
ducibility of VAFs and the resulting variant calls are also
reﬂected in the high sensitivity and PPV values of the serial
dilutions of the commercial HCV samples shown in Table 4,
because sensitivity and PPV are calculated with the variants
detected in the highest viral load dilutions being treated as
expected variants. For samples with viral load of approxi-
mately 105 IU/mL, because of the low level of HCV RNA in
extracted plasma RNA, more false positives and false
negative calls would likely appear if using a lenient VAF
cutoff such as 5%. Table 5 shows the trade-off between
sensitivity and PPV with different VAF cutoff values using
the commercial GT1a specimen as an example. To reach the
best compromise between sensitivity and PPV, a VAF
cutoff value of 10% is recommended for viral loads of
approximately 105 IU/mL.
Discussion
In this study, we report the development and performance
characterization of a template-independent NGS assay forf Five Commercial HCV Samples with VAF Cutoff at 5%
Sensitivity Speciﬁcity PPV NPV
0.990 0.999 0.974 1.000
0.925 0.997 0.898 0.998
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
0.959 0.939 0.999 0.999
0.990 0.941 0.999 1.000
1.000 0.960 0.999 1.000
0.979 0.990 1.000 1.000
0.939 0.996 0.869 0.998
0.982 1.000 0.982 1.000
0.994 1.000 0.982 1.000
0.988 1.000 0.988 1.000
1.000 1.000 0.994 1.000
0.969 0.999 0.952 0.999
0.982 1.000 0.988 1.000
0.994 0.999 0.959 1.000
GS on different NGS runs. For samples that had only one high viral load NGS
ere treated as the expected variants, and the rest of the nucleotide positions
ultiple high viral load NGS runs, the average of VAFs per nucleotide positions
ted variants, and the rest of the positions treated as nonvariants.
tive value; PPV, positive predictive value; VAF, variant allele fraction.
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Table 5 Sensitivity versus PPV at Different VAF Cutoff Values for Lower Viral Load Samples
Viral load
(IU/mL)
VAF cutoff
value (%)
No. of variants
called at highest
viral load
No. of variants
detected at speciﬁed
viral load
No. of variants
called by both
viral loads Sensitivity PPV Speciﬁcity NPV
4.8  105 5 298 303 295 0.990 0.974 0.999 1.000
4.8  105 10 268 267 264 0.985 0.989 1.000 0.999
4.8  105 15 239 231 227 0.950 0.983 0.999 0.998
4.8  104 5 298 364 279 0.936 0.766 0.986 0.997
4.8  104 10 268 261 241 0.899 0.923 0.997 0.996
4.8  104 15 239 213 204 0.854 0.958 0.999 0.995
Commercial GT1a sample was diluted at three different viral loads at 4.8  106, 4.8  105, and 4.8  104 IU/mL. At the three speciﬁed VAF cutoffs at 5%,
10%, and 15%, nucleotide variants in the HCV genomic region covering from NS2 to NS5B were called for each viral load. Treating the nucleotide variant calls
of the highest viral load as the expected variants, sensitivity, PPV, speciﬁcity, and NPV were calculated for the two lower viral load dilutions. For the lowest
viral load sample, there is a tradeoff between sensitivity and PPV at different VAF cutoff values, with VAF of 10% having the best compromise of sensitivity
versus PPV.
NPV, negative predictive value; PPV, positive predictive value; VAF, variant allele fraction.
Wei et alHCV whole genome sequencing without prior knowledge of
HCV genotype or subtypes. Key aspects of the development
include the optimization of a human rRNA depletion
method to enrich HCV RNA and the adaptation of a RNA-
seq based procedure for the low input mass RNA samples,
and the selection of a simple RNA extraction method over
the commonly used Qiagen’s QIAamp Viral RNA Mini Kit
method to obtain the same RNA yields while avoiding the
utilization of carrier RNA. The assay has multiple applica-
tions in HCV research, including HCV subtyping, mixed
genotype/subtyping infection detection, and more impor-
tant, the reliable detection of DAA-treatment resistance-
associated nucleotide variants at a prevalence level of 5%. It
addresses the challenge posed by HCV samples with less
well-known subtypes by obviating the need to design
genotype or subtype-speciﬁc PCR ampliﬁcationebased
sequencing assays for RAV detection, which is the current
practice. The TI-NGS assay offers another advantage over
the genotype or subtype-speciﬁc approach by avoiding
potential PCR primer caused biases in variant calling.
Furthermore, the TI-NGS method is more straightforward
and has less error-prone experimental procedures than
template-dependent sequencing. For template-dependent
sequencing assays, PCR primers and sometimes reverse
transcription primers have to be designed for individual
genotype, subtype, or individual patient’s HCV samples
with available nucleotide sequence information. During
sequence analysis, the correct primers have to be added to
the speciﬁc RNA samples to ensure successful PCR
ampliﬁcation; this step in particular is subject to human
error. Depending on amplicon sizes, different PCR condi-
tions such as polymerase extension time might have to be
adjusted. For the TI-NGS assay, all samples are treated with
the same reagents and the same experimental procedures,
without the need for speciﬁc primers or experimental con-
ditions; and the sequence results would cover the whole
HCV genome, not just the PCR primer targeted regions.
In contrast to the present work, previous work on TI-NGS
based methods for HCV whole genome sequencing18,19654focused on HCV samples with high viral loads and/or
with large amount of input RNA, for variants with VAFs
 15%. Furthermore, previous reports did not establish
assay performance characteristics such as sensitivity or
PPV.18,19 In the Hedskog et al18 article, the clinical samples’
viral loads seemed to have little correlation with percentage
NGS reads aligned to the HCV genome, and the percentage
reads aligned to HCV did not correlate with average
coverage. Three of six highest viral load samples (>107 IU/
mL) had an average coverage of <1000. In contrast, with
our TI-NGS assay, we show in Table 1 that the viral loads
are highly correlated with percentage reads aligned to HCV
genome and with average coverage. We speculate that the
much lower viral load-read coverage correlation of the
Hedskog et al’s18 TI-NGS method might be partially caused
by the lack of the human rRNA depletion step before
RNA-seq, because the high level of human rRNA in RNA
samples would reduce the percentage reads aligned to the
HCV even when the HCV viral load is high. In addition, we
also observed that we had more reproducible HCV coverage
patterns with HCV samples than the ones produced with the
Hedskog et al18 method with IVT RNA, a less challenging
sample because of the absence of human and other non-
HCV RNA. We suspect that the RNA-seq method used
by the Hedskog et al18 method might partially contribute to
the less reproducible HCV coverage patterns. In Iles et al’s19
article, although a similar RNA-seq method to our TI-NGS
was used, the method does not seem to include the human
rRNA depletion step, which might explain the large input
mass of 100 ng of total RNA (an amount not feasible in
clinical application) for their TI-NGS assay. In addition, the
Iles et al’s19 article studied HCV genome recombination,
which does not have the same sensitivity requirement of a
RAV detection assay. Overall, our data indicate that TI-
NGS is able to detect lower level mutations with better
precision with lower viral loads or RNA input masses.
Because this TI-NGS method provides sequence infor-
mation of any RNA presented in the extracted RNA sam-
ples, it is not surprising that we observed the presence ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
HCV Resistant Variant Detection with NGShuman mRNA, low levels of bacterial rRNA, and some-
times non-HCV viral RNA such as GB virus C. We have
detected high levels (>20% of all NGS reads) of GBV-C in
one clinical HCV sample, one NHV sample, and two
commercial HCV samples. The coinfection of GBV-C in
HCV patients is well documented and thus expected.20 The
presence of high levels of GBV-C coinfection might pose
challenges for accurate RAV detection for low viral load
HCV samples. The most abundant NGS reads aligned to the
human genome were 7SL RNA, which is the RNA
component of the signal recognition particle ribonucleo-
protein complex that directs protein trafﬁc within cells and
allows them to be secreted.21 In our HCV samples, the
percentage of NGS reads belonging to 7SL RNA ranged
from 2% to 29%. Methods to remove these RNA species
would further enhance the sensitivity of this assay in HCV
RAV detection.
Although the TI-NGS assay is not the best RAV detection
method for low viral load samples, the TI-NGS could be
clinically useful if related higher viral load samples were
available. In that scenario, it may be possible to use the
sequence information obtained from TI-NGS from the
higher viral load samples to guide the assay design of
template-dependent NGS. For example, we had a treatment
failure clinical sample with viral load of approximately 1500
IU/mL. For this sample, we used sequence information
obtained from TI-NGS from higher viral load samples of the
same patient to custom design a TD-NGS assay. The TD-
NGS was able to sequence the entire region from NS3 to
NS5B, while a subtype-speciﬁc Sanger sequencing assay
could only analyze one third of NS3 and full-length NS5A.
The TD-NGS results were 100% concordant with Sanger
sequencing at the genomic regions that could be ampliﬁed
by the PCR primers. Therefore, we recommend the
approach of designing TD-NGS with sequence information
obtained from TI-NGS when studying treatment failure
samples with less known subtypes and with low viral loads.
In summary, we have developed and validated a robust and
sensitive template-independent NGS assay for HCV whole
genome sequencing that overcomes the challenges presented
by the complex, diverse, and mutable genomes of HCV. This
single NGS assay can replace multiple genomic assays used in
HCV research, including HCV subtyping, mixed infection
determination, and DAA treatment resistanceeassociated
variant detection, with relatively straightforward experimental
procedures. This template-independent NGS assay can also be
easily adapted to study other viral or bacterial infections with
some modiﬁcations to the current bioinformatics pipeline.Acknowledgment
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